Ifrah Financial Services Inc. Grows Position in Pfizer Inc. (PFE)

Ifrah Financial Services Inc. lifted its stake in Pfizer Inc. (NYSE:PFE) by 11.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 28,288 shares of the biopharmaceutical company’s stock after buying an additional 2,793 shares during the period. Ifrah Financial Services Inc.’s holdings in Pfizer were worth $1,004,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in PFE. BlackRock Inc. lifted its stake in Pfizer by 2.8% during the fourth quarter. BlackRock Inc. now owns 452,745,609 shares of the biopharmaceutical company’s stock worth $16,398,445,000 after purchasing an additional 12,183,218 shares during the period. Bank of New York Mellon Corp lifted its stake in Pfizer by 11.9% during the fourth quarter. Bank of New York Mellon Corp now owns 70,738,885 shares of the biopharmaceutical company’s stock worth $2,562,162,000 after purchasing an additional 7,534,957 shares during the period. Geode Capital Management LLC lifted its stake in Pfizer by 3.1% during the fourth quarter. Geode Capital Management LLC now owns 63,123,777 shares of the biopharmaceutical company’s stock worth $2,281,563,000 after purchasing an additional 1,881,570 shares during the period. Fisher Asset Management LLC lifted its stake in Pfizer by 3.6% during the fourth quarter. Fisher Asset Management LLC now owns 36,372,349 shares of the biopharmaceutical company’s stock worth $1,317,407,000 after purchasing an additional 1,251,550 shares during the period. Finally, Schwab Charles Investment Management Inc. lifted its stake in Pfizer by 2.3% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 34,547,216 shares of the biopharmaceutical company’s stock worth $1,251,306,000 after purchasing an additional 790,097 shares during the period. Institutional investors and hedge funds own 69.44% of the company’s stock.

Pfizer opened at $36.38 on Wednesday, according to Marketbeat. The company has a market cap of $217.34 billion, a PE ratio of 13.73, a PEG ratio of 1.81 and a beta of 0.91. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.27 and a quick ratio of 0.98. Pfizer Inc. has a 1-year low of $32.32 and a 1-year high of $39.43.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, May 1st. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.74 by $0.03. The company had revenue of $12.91 billion during the quarter, compared to analyst estimates of $13.14 billion. Pfizer had a net margin of 41.29% and a return on equity of 25.29%. The company’s revenue was up 1.0% on a year-over-year basis. During the same quarter last year, the business posted $0.69 earnings per share. equities analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, June 1st. Investors of record on Friday, May 11th were issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.74%. The ex-dividend date was Thursday, May 10th. Pfizer’s dividend payout ratio is currently 51.32%.

A number of brokerages have commented on PFE. Morningstar set a $43.50 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Wednesday, May 2nd. Jefferies Financial Group restated a “neutral” rating and set a $39.00 price target on shares of Pfizer in a research note on Monday, May 14th. Berenberg Bank restated a “neutral” rating and set a $37.00 price target on shares of Pfizer in a research note on Wednesday, April 11th. Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price target for the company in a research note on Wednesday, April 11th. Finally, Morgan Stanley restated a “buy” rating and set a $43.00 price target on shares of Pfizer in a research note on Monday, June 11th. Three equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and ten have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $40.27.

In related news, CEO Ian C. Read sold 132,312 shares of the firm’s stock in a transaction that occurred on Tuesday, May 1st. The shares were sold at an average price of $36.01, for a total value of $4,764,555.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Laurie J. Olson sold 19,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 6th. The shares were sold at an average price of $36.45, for a total transaction of $692,550.00. Following the completion of the sale, the executive vice president now directly owns 98,644 shares of the company’s stock, valued at approximately $3,595,573.80. The disclosure for this sale can be found here. In the last three months, insiders sold 156,535 shares of company stock valued at $5,647,222. 0.06% of the stock is currently owned by company insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply